4-IODO-6-PHENYLPYRIMIDINE Property

Boiling point:

380.2±30.0 °C(Predicted)

Density 

1.728±0.06 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

DMSO: soluble10mg/mL (clear solution, warmed)

form 

powder

pka

-0.54±0.17(Predicted)

color 

white to beige

InChIKey

ZTCJXHNJVLUUMR-UHFFFAOYSA-N

Safety

Hazard Codes 

Xn

Risk Statements 

22-37/38-41

Safety Statements 

26-39

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H318Causes serious eye damage

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

4-IODO-6-PHENYLPYRIMIDINE Chemical Properties,Usage,Production

Uses

4-IPP has been used as a macrophage migration inhibitory factor (MIF) in conditioned medium (CM) for in vitro migration assay.

Definition

ChEBI: 4-iodo-6-phenylpyrimidine is a member of the class of pyrimidines carrying iodo and phenyl substituents at positions 4 and 6 respectively. It has a role as a macrophage migration inhibitory factor inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of pyrimidines, a biaryl and an organoiodine compound.

Biological Activity

Inhibitor of macrophage migration inhibitor factor (MIF). Acts as a suicide substrate to inactivate MIF catalytic and biological functions; inhibits MIF-associated liver enzyme activity in vivo . Also inhibits migration and anchorage independence of human lung adenocarcinoma cell lines in vitro .

Biochem/physiol Actions

4-Iodo-6-phenylpyrimidine (4-IPP) has the potential to be a new anti-polyploid therapeutic agent that may be utilized in patients with thyroid cancer to target polyploid tumor cells. It suppresses osteoclastogenesis by blocking the IMF-κB pathway. 4-IPP can be employed as a therapeutic target for macrophage migration inhibitory factor (MIF) to treat pathologic osteolytic bone diseases and postmenopausal bone loss. It can prevent the development and motility of lung adenocarcinoma cells and can stimulate apoptosis and mitotic death of thyroid carcinomas.

storage

Store at +4°C